Status:
TERMINATED
A Study of TAK-994 in Adults With Narcolepsy
Lead Sponsor:
Takeda
Conditions:
Narcolepsy Type 1 (NT 1)
Eligibility:
All Genders
18-65 years
Phase:
PHASE2
Brief Summary
Adults with narcolepsy who have completed the TAK-994-1501 study will be able to take part in this study. The main aim of this study is to check if participants have side effects from TAK-994. Parti...
Detailed Description
The drug being tested in the study is called TAK-994. TAK-994, is being tested to treat participants with NT1. Participants who completed Part B of TAK-994-1501(NCT04096560) will be eligible for enrol...
Eligibility Criteria
Inclusion
- 1\. Participant with a diagnosis of Narcolepsy Type 1 (NT1) who has completed TAK-994-1501 Part B before enrollment (which will occur immediately following the final TAK-994-1501 assessments), and for whom the investigator has no clinical objection they be enrolled.
Exclusion
- 1\. Participant has a clinically significant moderate or severe ongoing AE related to the study drug from the prior study.
Key Trial Info
Start Date :
April 30 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 3 2021
Estimated Enrollment :
26 Patients enrolled
Trial Details
Trial ID
NCT04820842
Start Date
April 30 2021
End Date
November 3 2021
Last Update
December 26 2023
Active Locations (70)
Enter a location and click search to find clinical trials sorted by distance.
1
Wright Clinical Research
Alabaster, Alabama, United States, 35007
2
Mayo Clinic Arizona 300151190
Phoenix, Arizona, United States, 85054
3
CITrials - Bellflower
Bellflower, California, United States, 90706
4
Santa Monica Clinical Trials
Los Angeles, California, United States, 90025